Upcoming events – Novartis and Miragen hope for heartening data
Upcoming data could help Novartis broaden the reach of its heart failure drug Entresto, while Miragen awaits a key test of its microRNA approach.
Upcoming events – Anaptysbio and Retrophin await big readouts
Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
Upcoming events – binary outcomes for Inflarx and Achieve
Inflarx looks to its lead asset in a rare skin disease, while smoking cessation success could trigger partnering talks for Achieve Life Sciences.
Fibrocell gets a reality check
Promising data with Fibrocell’s epidermolysis bullosa gene therapy send the company down as funding worries kick in.
Upcoming events – Dermira awaits eczema results and Conatus gets another bash at Nash
Dermira hopes that lebrikizumab can beat Dupixent, while Conatus tries to overcome an earlier Nash setback.
Gene therapies go skin deep to tackle epidermolysis bullosa
Three gene therapy contenders, Abeona, Fibrocell and Krystal, are taking different approaches in the quest to cure epidermolysis bullosa.
Krystal gets more skin in the epidermolysis bullosa game
Krystal Biotech shares surged after positive data with its epidermolysis bullosa project, KB103, in just two patients. Now it needs to repeat the trick.
Upcoming events – Ascendis and Lilly hope for growth with pivotal data
Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.
Upcoming events – Phase III readouts loom for Urogen and Mediwound
Urogen is gearing up to release the results of a pivotal trial of its lead asset – and so is Mediwound.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.